Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics

Inclusion Criteria: Patients who meet the following criteria will be considered eligible to participate in the study: * The patient is ≥ 18 and \< 70 years of age, and gives informed consent * Clinical diagnosis of mild to moderate asthma of at least 6 months duration and age of onset \< 50 years * Presently using ICS at moderate doses (equivalent to 200-800 µg of budesonide or 88-500 µg of fluticasone daily) * ≥ 12% and ≥ 200 mL improvement in FEV1 to 4 puffs albuterol by metered-dose inhaler (MDI) at screening visit * Patient is willing to use acceptable form of birth control during trial and for one month thereafter * Ability to measure morning (AM) peak expiratory flow (PEF) on schedule using electronic peak flow meter (EPFM) and to complete the study diary correctly at least 70% of the time during the run-in period * After 7 day withdrawal from LABA therapy and overnight withdrawal from SABA therapy (except rescue medication), patient has between 55% - 80% of predicted FEV1 at CV2 Exclusion Criteria: A patient meeting any of the following criteria is not eligible for enrollment in the study: * A clinical diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, bronchiectasis, or other significant pulmonary disease other than asthma * History of upper or lower respiratory infection within 4 weeks of screening * History of asthma exacerbation requiring oral or systemic corticosteroids or hospital admission within 6 months of screening * History of myocardial infarction, or cardiac conduction abnormalities, including but not limited to atrial fibrillation, and paroxysmal atrial tachycardia * Hospitalization due to cardiac failure within the last 6 months * History of narrow angle glaucoma or obstructive uropathy * Current smokers or vapers, or former smokers with \> 10 pack-year (self-reported) history of smoking * Patients who presently use the following medications will not be eligible for participation: * Long-acting muscarinic receptor antagonist (LAMA) * LABA (but may be withdrawn and converted to SABA x 7 days prior to entry) * Leukotriene pathway blockers * Anti-IgE antibody (Xolair) within last 6 months prior to CV1 * Phosphodiesterase 4 (PDE4) inhibitors (e.g., Roflumilast) * Cromolyn * Methylxanthines (e.g., aminophylline and theophylline) * 5-Lipoxygenase inhibitor (e.g., Zileuton) * Allergies to LAMA therapies * History of life-threatening asthma exacerbation requiring ICU admission, mechanical ventilation, or tracheostomy